Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cochrane On Bisphosphonates for Prostate Cancer

Cochrane; 2017 Dec 26; Macherey, Monsef, et al

Men with bone metastases from prostate who took bisphosphonates or control regimens experienced similar responses to pain, according to a Cochrane review of 18 clinical trials. The reviews found that bisphosphonates:

  • Provided no clinically relevant difference in pain response vs placebo or no additional treatment, based on low quality evidence.
  • Reduced pain in 40 more men/1,000.
  • Appear to result in 58 fewer skeletal-related events/1,000.
  • Showed no clear difference in the number of men who died or took fewer pain killers.
  • Probably increased the number of men with nausea, based on moderate quality evidence.
  • Probably increased the number of men with kidney problems, based on moderate quality evidence.
  • Showed no clear difference in patients who experienced osteonecrosis of the jaw, based on very low quality evidence.
  • Probably decreased the number of men affected by disease progression, according to moderate quality evidence.

Citation:

Macherey S, Monsef I, Jahn F, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database of Syst Rev. 2017, Issue 12. Art. No.: CD006250. doi:10.1002/14651858.CD006250.pub2.

This Week's Must Reads

Apixaban surpasses DOACs in very elderly patients, Deitelzweig SB et al. Circulation. 2018 Nov 6;138[suppl 1]:A14900

Sickle cell: Daily hydroxyurea safe in African children, Tshilolo L et al. ASH 2018, Abstract 3

Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123

Similar VTE rates seen with tofacitinib, TNF inhibitors, Desai RJ et al. Arthritis Rheumatol. 2018;70(suppl 10), Abstract L09

Recurrence risk high regardless of VTE classification, Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4